PMID- 21657995
OWN - NLM
STAT- MEDLINE
DCOM- 20120905
LR  - 20190918
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 13
IP  - 3
DP  - 2012 Mar
TI  - Genetic profile of SNP(s) and ovulation induction.
PG  - 417-25
AB  - Obtaining an adequate number of good quality oocytes while minimizing adverse 
      drug reactions (ADRs) and cycle cancellation rates is considered the gold 
      standard in controlled ovarian hyperstimulation (COH) for fertility treatment. 
      Patients who undergo IVF/ICSI cycles tend to present with different responses to 
      exogenous gonadotrophin administration. Research has shown that the secret 
      probably lies in the various single nucleotide polymorhisms (SNPs) in their 
      receptor genes. The decryption of human genome provided specialists with 
      additional information in assessing and even predicting ovarian response to COH. 
      In this context, the study of Pharmacogenomics, Pharmacogenetics and SNPs 
      unravels as a promising field in optimizing fertility treatment. Several SNPs in 
      FSH and estrogen receptor genes have been detected so far, but only three of 
      them, one in FSH receptor and two in estrogen receptor genes have been associated 
      with ovarian response to COH. It seems that the Asn/Ser variant of the FSH 
      receptor functions more efficiently, while the Ser/Ser and Asn/Asn variants have 
      a tendency to resist to FSH stimulation. With regards to estrogen receptor 1 
      (ESR1), the Pvull and the Xbal polymorphisms seem to be associated with 
      differences in the response to ovarian stimulation, while the Rsal polymorphism 
      in estrogen receptor 2 (ESR2) is currently under investigation. There exists 
      evidence supporting the hypothesis that a set of genes, all related to the FSH 
      hormone mechanism of action, may participate along with other factors to the 
      control of ovarian response to FSH, thus a cautious interpretation of 
      polymorphism detection results is considered mandatory. However, identifying 
      potential genetic markers that could predict ovarian response and implementing 
      them in routine screening tests for every woman entering an IVF/ICSI cycle, would 
      be able to tailor fertility treatment to each patients needs thus maximizing the 
      success rate and eliminating potential side-effects of fertility drugs.
FAU - Loutradis, D
AU  - Loutradis D
AD  - Division of Human Reproduction, IVF Unit, 1st Department of Obstetrics and 
      Gynecology, Alexandra Hospital, Athens University Medical School, Athens, Greece. 
      loutradi@otenet.gr
FAU - Theofanakis, C
AU  - Theofanakis C
FAU - Anagnostou, E
AU  - Anagnostou E
FAU - Mavrogianni, D
AU  - Mavrogianni D
FAU - Partsinevelos, G A
AU  - Partsinevelos GA
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Genetic Markers)
RN  - 0 (Receptors, FSH)
SB  - IM
MH  - Estrogen Receptor alpha/genetics
MH  - Estrogen Receptor beta/genetics
MH  - Female
MH  - Genetic Markers/genetics
MH  - Humans
MH  - Infertility, Female/*genetics/*therapy
MH  - Ovulation Induction/*methods
MH  - Pharmacogenetics/methods
MH  - *Polymorphism, Single Nucleotide
MH  - Receptors, FSH/genetics
EDAT- 2011/06/11 06:00
MHDA- 2012/09/06 06:00
CRDT- 2011/06/11 06:00
PHST- 2010/07/02 00:00 [received]
PHST- 2010/10/25 00:00 [accepted]
PHST- 2011/06/11 06:00 [entrez]
PHST- 2011/06/11 06:00 [pubmed]
PHST- 2012/09/06 06:00 [medline]
AID - BSP/CPB/E-Pub/000248-12-17 [pii]
AID - 10.2174/138920112799361954 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2012 Mar;13(3):417-25. doi: 10.2174/138920112799361954.